Results 331 to 340 of about 95,754 (365)

Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?

Hepatology, 2022
Treatment of primary biliary cholangitis (PBC) with ursodeoxycholic acid (UDCA) is not always sufficient to prevent progression to hepatic decompensation and/or need for liver transplant.
M. Mayo
semanticscholar   +1 more source

Gut microbiota-derived butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis.

Gastroenterology
BACKGROUND & AIMS Gut dysbiosis and myeloid-derived suppressor cells (MDSCs) are implicated in primary biliary cholangitis (PBC) pathogenesis. However, it remains unknown whether gut microbiota or their metabolites can modulate MDSCs homeostasis to ...
Rui Wang, Bo Li, Bingyuan Huang, Yikang Li, Qiaoyan Liu, Zhuwan Lyu, Ruiling Chen, Qiwei Qian, Xueying Liang, Xiting Pu, Yi Wu, Yu Chen, Q. Miao, Qixia Wang, M. Lian, Xiao Xiao, P. Leung, M. Gershwin, Z. You, Xiong Ma, R. Tang   +20 more
semanticscholar   +1 more source

Primary Biliary Cholangitis: personalizing second-line therapies.

Hepatology
Primary biliary cholangitis (PBC) is an enigmatic, autoimmune disease targeting the small intralobular bile ducts resulting in cholestasis and potentially progression to biliary cirrhosis.
Cynthia Levy, C. Bowlus
semanticscholar   +1 more source

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape.

American Journal of Gastroenterology
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are rare, chronic cholestatic diseases that can progress to liver failure. The goals of treatment are to halt the progression of liver disease to cirrhosis and/or liver failure ...
Sheena Bhushan, Aalam Sohal, Kris V Kowdley, Facg Faasld Agaf   +3 more
semanticscholar   +1 more source

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.

American Journal of Gastroenterology, 2020
OBJECTIVES In primary biliary cholangitis (PBC), bilirubin and alkaline phosphatase (ALP) are widely established as independent predictors of prognosis.
C. F. Murillo Perez, M. Harms, K. Lindor, H. V. van Buuren, G. Hirschfield, C. Corpechot, A. J. van der Meer, J. Feld, A. Gulamhusein, W. Lammers, C. Ponsioen, M. Carbone, A. Mason, M. Mayo, P. Invernizzi, P. Battezzati, A. Floreani, A. Lleo, F. Nevens, K. Kowdley, Tony Bruns, G. Dalekos, N. Gatselis, D. Thorburn, P. Trivedi, X. Verhelst, A. Parés, H. Janssen, B. Hansen   +28 more
semanticscholar   +1 more source

Epigenetics of Primary Biliary Cholangitis

2020
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease with non-suppurative destruction of the intrahepatic bile ducts. The interplay of genetics and environmental triggers contributes to the onset of the disease and subsequently results in cholestasis and progressive fibrosis.
Yikang, Li, Ruqi, Tang, Xiong, Ma
openaire   +2 more sources

New Treatment Paradigms in Primary Biliary Cholangitis.

Clinical Gastroenterology and Hepatology, 2023
C. Levy, M. Manns, G. Hirschfield
semanticscholar   +1 more source

Primary biliary cholangitis

Medicine, 2019
Abstract Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by lymphocytic destruction of the small, intrahepatic bile ducts, causing chronic cholestasis and progressive fibrosis that eventually leads to biliary cirrhosis.
openaire   +1 more source

Proteomics in Primary Biliary Cholangitis

2019
Primary biliary cholangitis is a chronic cholestatic liver disease characterized by the presence of serum antimitochondrial antibodies and immune-mediated destruction of the small and medium-sized intrahepatic bile ducts. However, the pathophysiology of primary biliary cholangitis has not yet been completely elucidated.
You, Li, Ruqui, Tang, Patrick S C, Leung, M Eric, Gershwin, Xiong, Ma   +4 more
openaire   +2 more sources

New Therapies on the Horizon for Primary Biliary Cholangitis

Drugs, 2023
Atsushi Tanaka
semanticscholar   +1 more source